Extra hepatic cancers are the leading cause of death in cirrhotic patients achieving HBV control or HCV eradication.
Fiche publication
Date publication
avril 2018
Journal
Hepatology (Baltimore, Md.)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BRONOWICKI Jean-Pierre, Pr DI MARTINO Vincent
Tous les auteurs :
Allaire M, Nahon P, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Nguyen-Khac E, Bernard-Chabert B, Zucman D, Di Martino V, Sutton A, Letouzé E, Audureau E, Roudot-Thoraval F,
Lien Pubmed
Résumé
Data on extrahepatic cancers (EHC) in compensated viral cirrhosis are limited. The objective of the prospective multicenter ANRS CO12 CirVir cohort was to assess the occurrence of all clinical events in patients with compensated viral cirrhosis, including all types of cancer.
Mots clés
Adult, Aged, Antiviral Agents, therapeutic use, Carcinoma, Hepatocellular, epidemiology, Cohort Studies, Databases, Factual, Disease Progression, Female, France, Hepatitis B, Chronic, complications, Hepatitis C, Chronic, complications, Humans, Liver Cirrhosis, epidemiology, Liver Neoplasms, epidemiology, Male, Middle Aged, Neoplasms, mortality, Prognosis, Prospective Studies, Risk Assessment, Survival Analysis
Référence
Hepatology. 2018 Apr 16;: